Compare Medpace Holdings Inc (MEDP) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs 3M Company — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while 3M Company trades at $159.96 (market cap $84.36B). The key difference: 3M Company is far larger — about 5× Medpace Holdings Inc's market cap, and 3M Company pays a 1.91% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and 3M Company for 169 Days on average.
| MEDP | MMM | |
|---|---|---|
Market Cap | $16.82B | $84.36B |
Volume | 223,093 | 2,325,301 |
Sector | Health | Industrials |
52-Week High | $630.19 | $183.79 |
52-Week Low | $393.42 | $141.10 |
Typical Hold Time | 14 Days | 169 Days |
Enterprise Value | $16.44B | $93.58B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
3M (MMM) trades at $163.57, up 0.89% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while news highlights operational progress and litigation management.
Outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high debt, weak consumer demand, and technical bearishness. The stock offers potential upside to analyst targets if margin gains and industrial strength persist amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
